- $700,000,000 of 2.250% fixed rate senior notes maturing in March 2020 issued by Teva Pharmaceutical Finance IV, LLC; and
- $1,300,000,000 of 2.950% fixed rate senior notes maturing in December 2022 issued by Teva Pharmaceutical Finance Company BV
U.S. Patent Office allows Mylan to go after half a dozen patents tied to Allergan's dry eye franchise Restasis.
The drugmaker is down nearly 46% year to date, which has created a great buying opportunity.
Wait for a bounce and then a retest before stepping up to buy.